文献速递银屑病与炎症性皮肤病

外用brepocitinib乳膏治疗轻中度慢性斑块状银屑病的疗效与安全性:一项IIb期随机双盲载体对照平行组研究

Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
PubMed 文献 · Br J Dermatol · 2023-01-01

这项IIb期多中心随机双盲研究纳入344例轻中度斑块状银屑病患者,评估外用brepocitinib(酪氨酸激酶2/JAK1抑制剂)多个剂量的疗效与安全性。结果显示,与相应载体对照相比,各剂量组在主要和关键次要疗效终点上均未达到统计学显著差异;brepocitinib耐受性良好,不良事件发生率组间相似。

要点

  • 外用brepocitinib各剂量组在12周PASI评分变化和PGA应答率上均未显著优于载体对照。
  • 从第8周起,所有每日两次brepocitinib组的PASI评分变化与载体分离。
  • brepocitinib耐受性良好,不良事件发生率组间相似;1例1.0%每日一次组出现带状疱疹。

核心结论

  • 外用brepocitinib耐受性良好,但在所评估剂量下治疗轻中度斑块状银屑病体征和症状时,与载体相比未产生统计学显著变化。

研究设计与样本

  • IIb期多中心随机双盲研究,分两阶段进行,共随机分配344例轻中度斑块状银屑病参与者。
  • 第一阶段参与者接受8种治疗之一为期12周:brepocitinib 0.1%每日一次、0.3%每日一次或每日两次、1.0%每日一次或每日两次、3.0%每日一次,或载体每日一次或每日两次。
  • 第二阶段参与者接受brepocitinib 3.0%每日两次或载体每日两次。
  • 主要终点为第12周银屑病面积和严重程度指数(PASI)评分较基线的变化,采用协方差分析。
  • 关键次要终点为第12周达到医师总体评估应答(评分为清除(0)或几乎清除(1)且较基线改善≥2分)的参与者比例。

主要发现

  • 第12周时,brepocitinib每日一次组的PASI评分较基线最小二乘均值变化范围为-1.4至-2.4,载体每日一次组为-1.6。
  • 第12周时,brepocitinib每日两次组的PASI评分较基线最小二乘均值变化范围为-2.5至-3.0,载体每日两次组为-2.2。
  • 从第8周起,所有brepocitinib每日两次组的PASI评分较基线变化与载体分离。
  • brepocitinib耐受性良好,不良事件发生率组间相似;brepocitinib 1.0%每日一次组有1例参与者出现颈部带状疱疹的治疗相关不良事件。

关键数值与推荐

  • 主要终点:第12周PASI评分较基线变化,brepocitinib各剂量组与相应载体对照相比均未达统计学显著差异。
  • 关键次要终点:第12周PGA应答率,brepocitinib各剂量组与相应载体对照相比均未达统计学显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plaque psoriasis (PsO) is an inflammatory skin disease driven, in part, by the activation of Janus kinase (JAK) signalling pathways. OBJECTIVES: To assess the efficacy and safety of multiple doses of topical brepocitinib, a tyrosine kinase 2/JAK1 inhibitor, in participants with mild-to-moderate PsO. METHODS: This phase IIb multicentre randomized double-blind study was conducted in two stages. In stage 1, participants received one of eight treatments for 12 weeks: brepocitinib 0.1% once daily, 0.3% once or twice daily, 1.0% once or twice daily, 3.0% once daily, or vehicle once or twice daily. In stage 2, participants received brepocitinib 3.0% twice daily or vehicle twice daily. The primary endpoint was the change from baseline in Psoriasis Area and Severity Index (PASI) score at week 12, analysed using analysis of covariance. The key secondary endpoint was the proportion of participants who achieved a Physician Global Assessment response [score of clear (0) or almost clear (1) and an improvement of ≥ 2 points from baseline] at week 12. Additional secondary endpoints included the difference vs. vehicle in change from baseline in PASI, using mixed-model repeated measures, and the change from baseline in Peak Pruritus Numerical Rating Scale at week 12. Safety was monitored. RESULTS: Overall, 344 participants were randomized. Topical brepocitinib did not result in statistically significant changes compared with respective vehicle controls in the primary or key secondary efficacy endpoints for any dose group. At week 12, least squares mean change from baseline in PASI score ranged from -1.4 to -2.4 for the brepocitinib once-daily groups vs. -1.6 for vehicle once daily, and from -2.5 to -3.0 for the brepocitinib twice-daily groups vs. -2.2 for vehicle twice daily. From week 8, change from baseline in PASI score separated from vehicle in all brepocitinib twice daily groups. Brepocitinib was well tolerated, with adverse events (AEs) occurring at similar rates across groups. One participant in the brepocitinib 1.0% once-daily group developed a treatment-related AE of herpes zoster in the neck area. CONCLUSIONS: Topical brepocitinib was well tolerated but did not result in statistically significant changes compared with vehicle when administered at the doses evaluated to treat signs and symptoms of mild-to-moderate PsO.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Landis MN, Smith SR, Berstein G, et al. Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study. Br J Dermatol. 2023. PMID: 36972293. doi:10.1093/bjd/ljad098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。